Roche, together with the Blueprint will create a gene therapy for cancer

Roche and Blueprint signed an agreement worth 1.7 billion dollars on the joint development of genetic methods of treatment of malignant tumors. Experimental therapy is designed for patients with rare tumors, writes Reuters.

Under the agreement, Roche will pay 675 million dollars and will hold an equity investment in the capital of the Blueprint for rights to palsetine (pralsetinib). It is expected that this drug, used for treatment of non-small cell lung cancer with RET rearrangement may be approved by the FDA this fall.

The company also Blueprint can get from Roche another 927 million USD in case of registration of the drug and its success in the market.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]